JASJIT SINGH: Open Payments
NPI 1265466197 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$169,239 in 297 payments from 16 companies in 2025. Trend: 2023 $55,460 · 2024 $66,579 · 2025 $169,239
Speaker / faculty: $89,232Honoraria: $45,225Travel & lodging: $17,024Consulting: $13,375Food & beverage: $4,349Education: $35
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 90 | $60,196 |
| Axsome Therapeutics, Inc. | 59 | $49,310 |
| E.R. Squibb & Sons, L.L.C. | 51 | $38,362 |
| Alkermes, Inc. | 45 | $20,318 |
| Neurocrine BioSciences, Inc. | 12 | $202 |
| Janssen Pharmaceuticals, Inc | 4 | $154 |
| Collegium Pharmaceutical, Inc. | 7 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $114 |
| Supernus Pharmaceuticals, Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
Products named: CAPLYTA, Auvelity, COBENFY, LYBALVI, ARISTADA, INGREZZA, Jornay PM, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
